Appendix Table 1.
Description of antiretroviral regimes in each NRTI combination in HIV-positive individuals, CoVIHd Collaboration, Spain, February-December 2020
| TAF/FTC N = 20,432 | TDF/FTC N = 6,160 | ABC/3TC N = 13,715 | Other N = 11,251 | ||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| BIC/TAF/FTC | 7,517 (37·1) | EFV/TDF/FTC | 2,186 (35·5) | DTG/ABC/3TC | 9,204 (67·1) | DTG/3TC | 3,832 (34·1) |
| EVG/COBI/TAF/FTC | 3,937 (19·4) | RPV/TDF/FTC | 1,340 (21·7) | NVP+ABC/3TC | 1,083 (7·9) | DTG/RPV | 1,747 (15·5) |
| RPV/TAF/FTC | 3,695 (18.2) | RAL+TDF/FTC | 692 (11.2) | RPV+ABC/3TC | 1,043 (7.6) | bDRV | 1,688 (15.0) |
| DRV/COBI/TAF/FTC | 3,210 (15.8) | bDRV+TDF/FTC | 624 (10.1) | RAL+ABC/3TC | 961 (7.0) | bDRV+3TC | 1,200 (10.7) |
| RAL+TAF/FTC | 744 (3.7) | DTG+TDF/FTC | 619 (10.0) | bDRV+ABC/3TC | 560 (4.1) | bDRV+DTG | 796 (7.1) |
| DTG+TAF/FTC | 682 (3.4) | NVP+TDF/FTC | 325 (5.3) | EFV+ABC/3TC | 554 (4.0) | bDRV+RAL | 520 (4.6) |
| NVP+TAF/FTC | 396 (1.9) | EVG/COBI/TDF/FTC | 140 (2.3) | ATVr+ABC/3TC | 108 (0.8) | bDRV+RPV | 221 (2.0) |
| EFV+TAF/FTC | 91 (0.4) | bATV+TDF/FTC | 86 (1.4) | ETV+ABC/3TC | 87 (0.6) | bDRV+ETV | 144 (1.3) |
| Other | 160 (0.8) | LPVr+TDF/FTC | 50 (0.8) | Other | 115 (0.8) | RAL+ETV | 143 (1.3) |
| ETV+TDF/FTC | 42 (0.7) | DTG | 136 (1.2) | ||||
| Other | 56 (0.9) | CAB+RPV | 126 (1.1) | ||||
| RAL+3TC | 112 (1.0) | ||||||
| Other | 586 (5.2) | ||||||
ABC, abacavir; BIC, Bictegravir; bATV, Atazanavir boosted; bDRV, Darunavir boosted; CAB, Cabotegravir; COBI, Cobicistat; DRV, Darunavir; DTG, Dolutegravir; EFV, Efavirenz; EVG, Elvitegravir; ETV, Etravirine; FTC, Emtricitabine; LPVr, Lopinavir/ritonavir; RAL, RaltegravirNVP, Nevirapine; RPV, Rilpivirine; TAF, Tenofovir alafenamide; 3TC, Lamivudine.